Angioblast Systems Inc. announced successful initial safety results following commencement of the world’s first clinical trial to use allogeneic adult stem cells obtained from an unrelated, universal ...
UBS Securities, a global investment services firm, brought an action against Angioblast Systems Inc., a biotechnology company, for breach of contract and indemnification. Angioblast alleged that UBS ...
Melbourne, May 12, 2010 (ABN Newswire) - Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB) (OTC:MBLTY) today announced that it will acquire its United States associate company, ...
Mesoblast chief executive Silviu Itescu has refused to answer questions over a share deal in 2011 while the biotech’s accumulated losses reach around $850 million today. In December 2010 Mesoblast ...
The strong rally in Mesoblast's share price came to an abrupt end on Friday when the stock suffered its worst one-day sell-off in nearly a year. This followed news that its US-based associate company, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results